Cardinal Health reported robust fourth-quarter and full fiscal year 2025 results, with full-year non-GAAP diluted earnings per share (EPS) increasing 9% to $8.24. Consolidated fiscal year 2025 revenues were $222.6 billion, a 2% decrease from fiscal year 2024, but increased 18% when excluding the impact of a previously communicated customer contract expiration.
The Pharmaceutical and Specialty Solutions segment delivered strong performance, with full-year profit increasing 12% to $2.3 billion. The Global Medical Products and Distribution (GMPD) segment also showed significant improvement, with full-year profit increasing 47% to $135 million. The 'Other' segment, including at-Home Solutions and Nuclear and Precision Health Solutions, saw full-year profit rise 22% to $516 million.
Based on this momentum, Cardinal Health raised its fiscal year 2026 non-GAAP diluted EPS outlook to $9.30 to $9.50, an increase of $0.20 from its preliminary outlook. This updated guidance reflects increased contributions from the Pharmaceutical and Specialty Solutions segment and the growth businesses reported in 'Other', signaling confidence in continued double-digit growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.